The Medicare drug price negotiation and inflation rebate provisions in the Build Back Better legislation under review in the US House would lower costs and/or raise government revenues by a collective $163bn over 10 years, the Congressional Budget Office estimates in a score released on 18 November.
Medicare Price Negotiation, Inflation Rebate Legislation Would Generate $163Bn, CBO Says
Score of slimmed down Medicare negotiations in the Build Back Better legislation is $79bn, a far cry from the $456bn in savings projected from the draconian HR 3. But the bill’s overall impact on the deficit means that pharma might get a total reprieve – or go back on the chopping block.